Last updated: February 23, 2024
Sponsor: Rahem Fertility Center
Overall Status: Active - Recruiting
Phase
4
Condition
In Vitro Fertilization
Treatment
estradiol valerate and letrozole
letrozole 2,5 mg tablet
Clinical Study ID
NCT06181305
endometrial preparation
Ages 18-37 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Women aged between 18 and 37 years with either regular cycles or oligomenorrhoea oramenorrhoea.
- Women undergoing FET cycles.
- Participants should have at least one good-quality blastocyst available forvitrification and also for transfer after warming.
- Participants having optimal endometrium before starting luteal phase support
Exclusion
Exclusion Criteria:
- Women who will refuse to participate in in the study.
- Women who will not reach the optimal endometrium.
- Participants that don't have at least one good-quality blastocyst for transfer afterwarming.
- PGT embryos will be excluded.
Study Design
Total Participants: 210
Treatment Group(s): 2
Primary Treatment: estradiol valerate and letrozole
Phase: 4
Study Start date:
February 24, 2024
Estimated Completion Date:
December 25, 2024
Study Description
Connect with a study center
Rahem fertility center
Zagazig, 44511
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.